Novo CEO Doustdar 'Very Optimistic' About CagriSema
Open the sourceReported by Bloomberg, bloomberg.com, 4 November 2026
50Impact 50 of 100, routine
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Muhabbit only has the headline for this one. The full report is at bloomberg.com.
Named in this story
Novo Nordisk A/S, Mike Doustdar, CagriSema, Ozempic, Wegovy, FDA